MondegarAI
Ishara Investments LP

Q1 2026 · 13F-HR

Ishara Investments LPholdings as filed

Filed 2026-05-15 · accession 0002111609-26-000002

$105.6M
Reported value
37
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · Ishara Investments LP · Q1 2026

AI · grounded in 13F

Ishara Investments LP initiated a new position in AXSM valued at $6.9M. The fund also added new stakes in Kalvista Pharmaceuticals Inc for $5.6M and ARWR for $3.5M. On the sell side, the fund closed its position in NUVB for $3.6M and exited BBIO for $2.8M. Additionally, the fund trimmed its holding in ANNX by 76.8%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74006W207PRAXPRAXIS PRECISION MEDICINES I$7.3M6.88%22,550CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC.$6.9M6.56%41,000CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$6.6M6.25%20,500PUTSOLE
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$5.9M5.63%1,025,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$5.6M5.27%276,750CommonSOLE
03152W109AM6AMICUS THERAPEUTIC$5.3M5.05%369,000CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$4.6M4.39%82,000CommonSOLE
92337C203VSTMVERASTEM INC$4.3M4.11%820,000CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$3.7M3.46%174,250CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$3.5M3.29%55,350CommonSOLE
92243G108PCVXVAXCYTE INC$3.3M3.16%57,400CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$3.3M3.12%82,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$3.3M3.11%110,700CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$3.2M3.08%174,250CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$2.9M2.72%1,230,000CommonSOLE
80706P103SRRKSCHOLAR ROCK HLDG CORP$2.8M2.67%57,400CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$2.7M2.59%123,000CommonSOLE
039697107ARDXARDELYX INC$2.7M2.56%451,000CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$2.2M2.10%82,000CommonSOLE
372303206GMABGENMAB A/S$2.2M2.08%82,000CommonSOLE
23306J309DBVTDBV TECHNOLOGIES S A$2.1M2.03%102,500CommonSOLE
14888U101CPRXCATALYST PHARMACEUTICALS INC$2.0M1.92%82,000CommonSOLE
829401108SIONSIONNA THERAPEUTICS INC$2.0M1.87%49,200CommonSOLE
21217B100CTNMCONTINEUM THERAPEUTICS INC$1.9M1.76%142,000CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$1.7M1.61%5,125CommonSOLE
53220K504LGNDLIGAND PHARMACEUTICALS INC$1.6M1.55%8,200CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$1.5M1.47%49,200CommonSOLE
N44445109IMTXIMMATICS N.V$1.5M1.43%153,750CommonSOLE
528872302LXRXLEXICON PHARMACEUTICALS INC$1.4M1.33%902,000CommonSOLE
07373V105BEAMBEAM THERAPEUTICS INC$1.4M1.29%57,400CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$1.3M1.23%102,500CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$1.2M1.12%36,900CommonSOLE
03589W102ANNXANNEXON INC$965,3450.91%174,250CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$819,6720.78%24,600CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$740,4350.70%140,500CommonSOLE
69366J200PTCTPTC THERAPEUTICS INC$698,3330.66%10,250CommonSOLE
38341P102GOSSGOSSAMER BIO INC$269,3700.26%820,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.